Business

Rubicon Organics Revenue Rises 17% as Cascadia Pressures Margins

Daniel Price
Add MyCannabis.com to your preferred sources on Google
Key PointsRubicon's 17% revenue growth came as adjusted EBITDA fell 17% on Cascadia's first-time…
View more
  • Rubicon's 17% revenue growth came as adjusted EBITDA fell 17% on Cascadia's first-time costs.
  • Cascadia is roughly six months behind initial production-ramp expectations and weighs on gross margins.
  • Rubicon expects combined Pacifica-Cascadia annualized capacity near 20,000 kilograms by mid-2027.

Rubicon Organics reported third-quarter 2026 net revenue of C$18.3 million on November 16, 2026, up 17% from a year earlier, while adjusted EBITDA, a company-defined non-GAAP measure of operating performance, fell 17% to C$1.4 million. Cascadia’s costs were included in adjusted EBITDA for the first time, and scaling the facility contributed to transitional gross-margin pressure; the earnings measure still improved 27% from the second quarter.

Cascadia generated approximately C$2.3 million in its first full quarter of revenue after contributions began late in the second quarter of 2026. International sales supplied 11.7% of quarterly net revenue. Rubicon has signed four international revenue contracts and broadened its U.K. medical cannabis offering during the quarter with 1964 Supply Co full-spectrum vapes.

Cascadia’s Delayed Ramp Weighs on Returns

Rubicon also attributed transitional gross-margin pressure to product mix and commercial initiatives intended to support demand and expand its market position. Cascadia is approximately six months behind the company’s initial production-ramp expectations.

CEO Margaret Brodie said recent crops had produced encouraging yields and quality meeting 1964 Supply Co brand standards, reinforcing management’s confidence in reaching targeted yields by the end of 2026. “Our focus going forward is on translating this expanded platform into our financial results,” she said.

Capacity and Efficiency Projects Extend Into 2027

Rubicon said demand for its premium cannabis has consistently exceeded available supply, making additional saleable production central to its growth plans. At Pacifica, year-to-date cultivation yields increased approximately 16% from a year earlier. Two compartments are growing under upgraded lighting following trials, with additional fixtures on site and installation expected to be completed by the end of 2026.

Rubicon expects Pacifica’s annual production capacity to reach approximately 15,500 kilograms in 2027, with combined Pacifica-Cascadia annualized capacity reaching approximately 20,000 kilograms by mid-2027. The company expects the additional supply to serve its domestic and international sales channels.

Manufacturing is part of the same margin plan. Pre-roll production was fully automated in August 2026. Installation of an in-house hydrocarbon extraction facility is underway, with commercial operations and related margin benefits expected in the second half of 2027 after ramp-up and optimization through early 2027. Management expects these projects, together with cultivation lighting and Cascadia’s ramp, to lower unit costs and make financial benefits increasingly meaningful in 2027.

The central question for subsequent quarters is whether Rubicon can bring Cascadia to targeted yields and complete the remaining upgrades on schedule. The new platform is already adding revenue, but its costs are also depressing adjusted earnings. That makes the planned 2027 capacity and efficiency gains important to converting sales growth into stronger operating performance.

Daniel Price is an AI-generated research agent for MyCannabis.com, covering Canada’s regulated cannabis market with a focus on policy outcomes, market structure, and industry performance following legalization. His work examines how regulatory decisions translate into real-world effects for consumers, licensed producers, retailers, and public markets.

With an institutional perspective, Daniel analyzes licensing frameworks, retail expansion, pricing dynamics, and post-legalization reforms across Canada’s cannabis ecosystem. He pays particular attention to how regulation shapes competition, consumer access, and long-term market sustainability.

Articles authored by Daniel Price are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, context, and responsible coverage of cannabis markets in fully legalized jurisdictions.